Restasis generic
Restasis is an ophthalmic emulsion owned by Abbvie and it was first authorized for market use on 23rd December, 2002. The drug contains cyclosporine as its active ingredient and holds a total of 10 patents, none of which have expired.
When will Restasis generic be available?
The generic for Restasis could potentially be released after 11th May, 2034. This possibility is primarily due to a patent for a protective cap for a dispenser, and a discharge device for discharging pharmaceutical and/or cosmetical liquids, which is set to expire on that date. This patent is one of the reasons why the Restasis generic release date is not earlier.
Restasis uses
Restasis is commonly used to increase tear production in patients suffering from keratoconjunctivitis sicca (dry eye). The effectiveness of this drug comes from its active ingredient, cyclosporine, which helps to provide therapeutic effects.
Restasis patent expiration
Restasis holds a range of patents, with the last one set to expire on 11th May, 2034. This patent is integral to the discharge device for discharging the pharmaceutical liquid. With this patent in place, the Restasis generic is unable to be released till then. Below is the detail of the patent: